GoldenGolden
BioNTech

BioNTech

BioNTech is a German company that develops immunotherapies for the treatment of cancer and other diseases.

Contents
Approach
PipelineCOVID-19
Timeline
Funding rounds
Products
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Primarily focused on developing individualized cancer therapy, BioNTech is a biotechnology company located in Mainz, Germany.

Approach

Their method revolves around several platforms in medicine; mRNA Therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. Coupled with their approach to patient specific needs, they have seen success in providing unique treatments.

  1. Sequencing patient's tumor
  2. Mapping of mutations
  3. Bioinformatic algorithms
  4. Selection of neoepitopes

Pipeline

COVID-19

BNT162 is BioNTech’s mRNA vaccine program aimed at preventing COVID-19 infection. It is the first product candidate from Project Lightspeed and leverages BioNTech’s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production, and its global clinical development capabilities, drawing on BioNTech’s network of global collaborators. BioNTech is partnered with Pfizer for co-development and distribution of BNT162 and with Fosun Pharma on the vaccine development in China.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
‌
BioNTech funding round, January 2018
270,000,000
January 2018
Redmile Group
Janus Henderson Investors
Invus
Fidelity Investments
‌
BioNTech funding round, January 2019
January 2019
Sanofi
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Özlem Türeci

Chief Medical Officer

Ryan Richardson

Chief Strategy Officer

Sean Marett

Chief Business and Chief Commercial Officer

Sierk Poetting

Chief Financial Officer and Chief Operating Officer

Ugur Sahin

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

BioNTech Corporate Video

https://youtu.be/-7QOo7LXsp0

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Pfizer, BioNTech to supply 120 mn doses of coronavirus vaccine to Japan
Reuters
July 31, 2020
@bsindia
BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy
Moderna, Pfizer begin Covid-19 vaccine trials, eye year-end launches
Agencies
July 28, 2020
@bsindia
The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by Covid-19
Coronavirus vaccine update: Oxford, Pfizer vaccines safe, give immunity
BS Web Team
July 21, 2020
@bsindia
There are 23 coronavirus vaccine candidates in human trials, including Moderna, AstraZeneca Plc, BioNTech, Novavax, Sinovac, CanSino Biologics and Inovio. Catch latest updates on Covid-19 vaccine
Britain signs deals with Pfizer, BioNTech, Valneva for Covid-19 vaccines
Reuters
July 20, 2020
@bsindia
Deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford
Pfizer, BioNTech's Covid-19 vaccines get US FDA's 'fast track' status
Reuters
July 13, 2020
@bsindia
If the ongoing studies are successful, and the vaccine candidate receives regulatory approval, the companies said they expect to make up to 100 million doses by the end of this year
Pfizer, BioNTech's Covid-19 drug shows encouraging results in early tests
AP | PTI
July 2, 2020
@bsindia
With its other potential candidates still in the earliest stage of testing, Pfizer aims to open a large-scale study this summer but cant yet say which shot is best to include
After CureVac nabs government backing, BioNTech sees $250M private investment
Ben Adams
June 29, 2020
FierceBiotech
As two of Germany's brightest COVID-19 pandemic vaccine biotechs continue to speed on with their clinical work, both have seen big cash injections to help them--but from very different sources.
Roche, BioNTech post 'low' response rate in cancer vaccine trial
Nick Paul
June 22, 2020
FierceBiotech
A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a "low" response rate. Nine of the 108 evaluable solid tumor patients responded when given the vaccine in combination with Tecentriq, although researchers pointed to immune response results to support continued study in other populations.
Here's what you need to know about WHO's top 8 COVID-19 vaccine candidates
May 18, 2020
@TIMESNOW
More than 100 COVID-19 vaccine candidates are in various stages of development with a handful of them already in early human trials. Three coronavirus vaccines have entered phase 2 clinical trials.
15 Prominent Pharma Companies in Vaccine Developments for COVID-19 - ResearchAndMarkets.com
April 7, 2020
news.google.com
COVID-19 is spreading throughout the world and vaccine developers have responded with unprecedented speed. Since the COVID-19 genome sequence was released in January, human trials of Moderna's vaccine candidate have already begun. Although the typical timeline for vaccine development can take up
Clinical trials for COVID-19 vaccine start, millions of dollars at stake
IANS
March 19, 2020
Livemint
From the US to China and in between, over 35 drug makers are fighting for a vaccine that can prevent new coronavirus (COVID-19).Medical experts in China claimed that Favipiravir, the active ingredient in a Japanese anti-flu medicine called Avigan, is 'clearly effective' in treating the coronavirus
Pfizer, BioNTech to co-develop potential coronavirus vaccine
Reuters Editorial
March 17, 2020
IN
U.S. drugmaker Pfizer Inc has signed a deal with Germany's BioNTech SE to co-develop a potential vaccine for the coronavirus using BioNTech's mRNA-based drug development platform, the companies said on Tuesday.
Pfizer weighs working with BioNTech on potential coronavirus vaccine - R&D head
Michael Erman
March 6, 2020
IN
Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE <22UAy.F> to develop vaccines for the coronavirus using BioNTech&#039;s mRNA-based drug development platform, Pfizer&#039;s R&D head told Reuters on Thursday.

References

BioNTech

biontech.de

Company attributes

Industry
Biotechnology
Medicine
Vaccine
Drug discovery
Cancer immunotherapy
‌
Therapeutics
Medical diagnostics
Location
Germany
Mainz
Company status
Active
Founder
‌
Christoph Huber
‌
Ugur Sahin
Full address
An der Goldgrube 12 55131 Mainz Germany
Crunchbase
crunchbase.com/organiz...ntech-ag
Investors
Invus
MIG Fonds
Jebsen Capital
Founded date
2008
Email address
info@biontech.de
Phone number
49 6131 9084-0
Fax number
49 6131 9084-390
Total funding amount (USD)
270,000,000

Categories

Related Topics

Contributors

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
FeaturesPricingEnterprise
Legal
Terms & ConditionsPrivacy Policy
Help
Help & ResourcesAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.